^
Association details:
| Biomarker: | ASS1 mutation |
|---|---|
| Cancer: | Malignant Pleural Mesothelioma |
| Drug: | cisplatin (DNA synthesis inhibitor) + pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) + Hepacid (pegargiminase) (Arginine depleter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms
Published date:
09/03/2020
Excerpt:
A total of 32 patients with ASS1-deficient MPM (11 epithelioid; 10 biphasic;11 sarcomatoid) who were chemonaive received weekly intramuscular pegargiminase (36 mg/m2) with Pem (500 mg/m2) and cisplatin (75 mg/m2) intravenously, every 3 weeks (six cycles maximum)....The disease control rate in 31 assessed patients was 93.5% (n = 29 of 31; 95% confidence interval [CI]: 78.6%-99.2%), with a partial response rate of 35.5% (n = 11 of 31; 95% CI: 19.2%-54.6%).
DOI:
10.1016/j.jtocrr.2020.100093
